Fierce Biotech:
November 11, 2014 | By John Carroll
Regeneron and its close partner Sanofi have cleared the final mid-stage hurdle for dupilumab in asthma patients, with several doses hitting the trial endpoint both for a subset of patients as well as the broad population. And the ambitious development team at Regeneron now plans to hustle into a pivotal late-stage program as they continue to make swift progress with a drug that promises to tackle a trio of conditions that share a core inflammatory trigger.
GSK are providing competition:
GlaxoSmithKline ($GSK) filed for an approval of its IL-5 asthma drug mepolizumab, with Teva (reslizumab) and AstraZeneca (benralizumab) trailing along the IL-5 pathway.
with a multi billion dollar market awaiting, not to mention the relief of suffering for patients.
I just shake my head at current sp
UNS Price at posting:
57.0¢ Sentiment: Hold Disclosure: Held